๐ก This study analyzed the impact of the FilmArray Blood Culture Identification Panel โ an amplification-based diagnostic test โ on the treatment and clinical outcomes of bloodstream infections, especially those linked to multidrug-resistant microorganisms.ย ย
๐ This retrospective study compared patients who underwent BCID testing with a historical control group that used conventional culture testing methods. Patients with bacteremia caused by carbapenem-resistant Enterobacterales and vancomycin-resistant enterococci were specifically analyzed.ย ย
๐ A total of 144 patients who underwent BCID testing and 214 patients who underwent conventional cultures were included. The 30-day mortality rate, time to effective antibiotic administration, and time to appropriate antibiotic administration did not differ significantly between the groups.ย ย
1. The BCID panel did not significantly change 30-day mortality rates or time to antibiotic administration.ย ย
2. BCID shortened the time to effective treatment for specific drug-resistant infections.ย ย
3. There was no observed change in 30-day mortality after adjusting for relevant variables.ย ย
4. Clinical outcomes didnโt improve significantly across patient subgroups with BCID testing.ย ย
5. BCIDโs clinical impact was limited due to partial antimicrobial susceptibility information and lack of real-time management.ย
๐ BCID reduced the time to administration of effective antibiotics in cases of CRE (39 h vs. 93 h) and VRE (50 h vs. 92 h) bacteremia. However, BCID was not significantly associated with 30-day mortality after adjusting for the Pitt bacteremia score and the Charlson comorbidity index.ย
๐ Overall, the use of BCID testing did not affect 30-day mortality or the overall clinical outcomes of bloodstream infections. However, it was beneficial in reducing the time to deliver effective antibiotic treatment for infections caused by certain multidrug-resistant organisms.
Link to the article : https://tinyurl.com/yx35span
